ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION Drug Patent Profile
✉ Email this page to a colleague
When do Allegra-d 12 Hour Allergy And Congestion patents expire, and what generic alternatives are available?
Allegra-d 12 Hour Allergy And Congestion is a drug marketed by Chattem Sanofi and is included in one NDA.
The generic ingredient in ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is fexofenadine hydrochloride; pseudoephedrine hydrochloride. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride; pseudoephedrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Allegra-d 12 Hour Allergy And Congestion
A generic version of ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION was approved as fexofenadine hydrochloride; pseudoephedrine hydrochloride by DR REDDYS LABS LTD on June 22nd, 2011.
Summary for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 75 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION at DailyMed |
Pharmacology for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
| Drug Class | Histamine-1 Receptor Antagonist alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists Histamine H1 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
US Patents and Regulatory Information for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Chattem Sanofi | ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | fexofenadine hydrochloride; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020786-002 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
See the table below for patents covering ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 117237 | PHARMACEUTICAL COMPOSITIONS OF PIPERIDINOALKANOL COMPOUNDS IN SOLID UNIT DOSAGE FORM | ⤷ Try a Trial |
| Japan | 4503907 | ⤷ Try a Trial | |
| Norway | 801014 | ⤷ Try a Trial | |
| New Zealand | 192653 | 4-SUBSTITUTED PIPERIDINO-ALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Try a Trial |
| New Zealand | 286116 | SUBSTANTIALLY PURE DIPHENYLMETHYL PIPERIDIN-1-YL SUBSTITUTED DIMETHYLPHENYLACETIC ACID AND ESTERS; PHARMACEUTICAL COMPOSITIONS | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
